Gene expression of insulin receptor, insulin-like growth factor increases and insulin-like growth factor-binding protein-3 reduces with increase in prostate size in benign prostatic hyperplasia

References

• Egan KB. The epidemiology of benign prostatic hyperplasia associated with lower urinary tract symptoms: prevalence and incident rates. Urol Clin North Am. 2016;43:289–297.
   PubMed Web of Science ®Google Scholar
• Khvostova E, Otpuschennikov A, Pustylnyak V, et al. Gene expression of androgen metabolising enzymes in benign and malignant prostatic tissues. Horm Metab Res. 2014;47:119–124.
   PubMed Web of Science ®Google Scholar
• Pradidarcheep W. Lower urinary tract symptoms and its potential relation with late onset hypogonadism. Aging Male. 2008;11:51–55.
   PubMed Web of Science ®Google Scholar
• Yassin A, Nettleship JE, Talib RA, et al. Effects of testosterone replacement therapy withdrawal and re-treatment in hypogonadal elderlymen upon obesity, voiding function and prostate safety parameters. Aging Male. 2016;19:64–69.
   PubMed Web of Science ®Google Scholar
• La Vignera S, Condorelli RA, Cimino L, et al. Late onset hypogonadism: the advantages of treatment with human chorionic gonadotropin rather than testosterone. Aging Male. 2016;19:34–39.
   PubMed Web of Science ®Google Scholar
• Amano T, Imao T, Takemae K, et al. Testosterone replacement therapy by testosterone ointment relieves lower urinary tractsymptoms in late onset hypogonadism patients. Aging Male. 2010;13:242–246.
   PubMed Web of Science ®Google Scholar
• Karazindiyanoğlu S, Cayan S. The effect of testosterone therapy on lower urinary tract symptoms/bladder and sexual functionsin men with symptomatic late-onset hypogonadism. Aging Male. 2008;11:146–149.
   PubMed Web of Science ®Google Scholar
• Efesoy O, Apa D, Tek M, et al. The effect of testosterone treatment on prostate histology and apoptosis in men with late-onset hypogonadism. Aging Male. 2016;19:79–84.
   PubMed Web of Science ®Google Scholar
• Meuleman EJ, Legros JJ, Bouloux PM, et al. Effects of long-term oral testosterone undecanoate therapy on urinary symptoms: data from a 1-year, placebo-controlled, dose-ranging trial in aging men with symptomatic hypogonadism. Aging Male. 2015;18:157–163.
   PubMed Web of Science ®Google Scholar
• Wada N, Hashizume K, Matsumoto S, et al. Dutasteride improves bone mineral density in male patients with lower urinary tract symptomsand prostatic enlargement: a preliminary study. Aging Male. 2016;19:12–14.
   PubMed Web of Science ®Google Scholar
• Lucia MS, Lambert JR. Growth factors in benign prostatic hyperplasia: basic science implications. Curr Urol Rep. 2008;9:272–278.
   PubMedGoogle Scholar
• Parsons JK, Carter HB, Partin AW, et al. Metabolic factors associated with benign prostatic hyperplasia. J Clin Endocrinol Metab. 2006;91:2562–2568.
   PubMed Web of Science ®Google Scholar
• Nandeesha H, Koner BC, Dorairajan LN, et al. Hyperinsulinemia and dyslipidemia in non-diabetic benign prostatic hyperplasia. Clin Chim Acta. 2006;370:89–93.
   PubMed Web of Science ®Google Scholar
• Urushima H, Inomata-Kurashiki Y, Nishimura K, et al. The effects of androgen deprivation therapy with weight management on serum aP2 and adiponectin levels in prostate cancer patients. Aging Male. 2015;18:72–76.
   PubMed Web of Science ®Google Scholar
• Hammarsten J, Högstedt B. Hyperinsulinaemia as a risk factor for developing benign prostatic hyperplasia. Eur Urol. 2001;39:151–158.
   PubMed Web of Science ®Google Scholar
• Vikram A, Jena GB, Ramarao P. Increased cell proliferation and contractility of prostate in insulin resistant rats: linking hyperinsulinemia with benign prostate hyperplasia. Prostate. 2010;70:79–89.
   PubMed Web of Science ®Google Scholar
• Yeh HC, Liu CC, Lee YC, et al. Associations of the lower urinary tract symptoms with the lifestyle, prostate volume, and metabolic syndrome in the elderly males. Aging Male. 2012;15:166–172.
   PubMed Web of Science ®Google Scholar
• Sarma AV, Kellogg Parsons J. Diabetes and benign prostatic hyperplasia: emerging clinical connections. Curr Urol Rep. 2009;10:267–275.
   PubMedGoogle Scholar
• Boucher J, Kleinridders A, Kahn CR. Insulin receptor signaling in normal and insulin-resistant states. Cold Spring Harb Perspect Bio. 2014;6:a009191.
   PubMed Web of Science ®Google Scholar
• Belfiore A, Frasca F, Pandini G, et al. Insulin receptor isoforms and insulin receptor/insulin-like growth factor receptor hybrids in physiology and disease. Endocr Rev. 2009;30:586–623.
   PubMed Web of Science ®Google Scholar
• Ulanet DB, Ludwig DL, Kahn CR, et al. Insulin receptor functionally enhances multistage tumor progression and conveys intrinsic resistance to IGF-1R targeted therapy. Proc Natl Acad Sci USA. 2010;107:10791–10798.
   PubMed Web of Science ®Google Scholar
• Zhang H, Fagan DH, Zeng X, et al. Inhibition of cancer cell proliferation and metastasis by insulin receptor downregulation. Oncogene. 2010;29:2517–2527.
   PubMed Web of Science ®Google Scholar
• Cox ME, Gleave ME, Zakikhani M, et al. Insulin receptor expression by human prostate cancers. Prostate. 2009;69:33–40.
   PubMed Web of Science ®Google Scholar
• Merseburger AS, Hennenlotter J, Simon P, et al. Activation of the PKB/Akt pathway in histological benign prostatic tissue adjacent to the primary malignant lesions. Oncol Rep. 2006;16:79–83.
   PubMed Web of Science ®Google Scholar
• Waalkes S, Simon P, Hennenlotter J, et al. Altered expression of Aktsignaling pathway parameters in prostate needle biopsies derived from benign, adjacent and cancerous tissue. Oncol Rep. 2010;23:1257–1260.
   PubMed Web of Science ®Google Scholar
• Heni M, Hennenlotter J, Scharpf M, et al. Insulin receptor isoforms A and B as well as insulin receptor substrates-1 and -2 are differentially expressed in prostate cancer. PLoS One. 2012;7:e50953.
   PubMed Web of Science ®Google Scholar
• Massoner P, Haag P, Seifarth C, et al. Insulin-like growth factor binding protein-3 (IGFBP-3) in the prostate and in prostate cancer: local production, distribution and secretion pattern indicate a role in stromal-epithelial interaction. Prostate. 2008;68:1165–1178.
   PubMed Web of Science ®Google Scholar
• Mehta HH, Gao Q, Galet C, et al. IGFBP-3 is a metastasis suppression gene in prostate cancer. Cancer Res. 2011;71:5154–5163.
   PubMed Web of Science ®Google Scholar
• Winkler G, Cseh K. Molecular mechanisms and correlations of insulin resistance, obesity, and type 2 diabetes mellitus. Orv Hetil. 2009;150:771–780.
   PubMedGoogle Scholar
• Frasca F, Pandini G, Sciacca L, et al. The role of insulin receptors and IGF-I receptors in cancer and other diseases. Arch Physiol Biochem. 2008;114:23–37.
   PubMedGoogle Scholar
• Christopoulos PF, Msaouel P, Koutsilieris M. The role of the insulin-like growth factor-1 system in breast cancer. Mol Cancer. 2015;14:43.
   PubMed Web of Science ®Google Scholar
• Chao W, D'Amore PA. IGF2: epigenetic regulation and role in development and disease. Cytokine Growth Factor Rev. 2008;19:111–120.
   PubMed Web of Science ®Google Scholar
• Cardillo MR, Monti S, Di Silverio F, et al. Insulin-like growth factor (IGF)-I, IGF-II and IGF type I receptor (IGFR-I) expression in prostatic cancer. Anticancer Res. 2003;23:3825–3835.
   PubMed Web of Science ®Google Scholar
• Ryan CJ, Haqq CM, Simko J, et al. Expression of insulin-like growth factor-1 receptor in local and metastatic prostate cancer. Urol Oncol. 2007;25:134–140.
   PubMed Web of Science ®Google Scholar
• Grimberg A. Mechanisms by which IGF-I may promote cancer. Cancer Biol Ther. 2003;2:630–635.
   PubMed Web of Science ®Google Scholar
• Kelley KM, Oh Y, Gargosky SE, et al. Insulin-like growth factor-binding proteins (IGFBPs) and their regulatory dynamics. Int J Biochem Cell Biol. 1996;28:619–637.
   PubMed Web of Science ®Google Scholar
• Seligson DB, Yu H, Tze S, et al. IGFBP-3 nuclear localization predicts human prostate cancer recurrence. Horm Canc. 2013;4:12–23.
   PubMed Web of Science ®Google Scholar
• Mardilovich K, Pankratz SL, Shaw LM. Expression and function of the insulin receptor substrate proteins in cancer. Cell Commun Signal. 2009;7:14.
   PubMed Web of Science ®Google Scholar
• Sreenivasulu K, Nandeesha H, Dorairajan LN, et al. Elevated insulin and reduced insulin like growth factor binding protein-3/prostate specific antigen ratio with increase in prostate size in Benign Prostatic Hyperplasia. Clin Chim Acta. 2017;469:37–41.
   PubMed Web of Science ®Google Scholar
• Grosman H, Fabre B, Lopez M, et al. Complex relationship between sex hormones, insulin resistance and leptin in men with and without prostatic disease. Aging Male. 2016;19:40–45.
   PubMed Web of Science ®Google Scholar